William Blair Upgrades Moderna (MRNA) to Outperform, 'we believe Moderna has a clear line of sight to revenue diversification from the COVID business
William Blair analyst Myles Minter upgraded Moderna (NASDAQ: MRNA) from Market ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)